Cai Tommaso, Luciani Lorenzo Giuseppe, Caola Iole, Mondaini Nicola, Malossini Gianni, Lanzafame Paolo, Mazzoli Sandra, Bartoletti Riccardo
Department of Urology, Santa Chiara Regional Hospital, Trento, Italy.
Urologia. 2013 Apr 24;80 Suppl 22:5-10. doi: 10.5301/RU.2013.10597. Epub 2013 Jan 16.
The therapeutic efficacy of CP/CPPS is not very satisfactory and the impact on young male's quality of life is considerable. The aim of the present study is to evaluate the efficacy of pollen extract associated with vitamins (DEPROX 500®) in order to improve the quality of life of young patients affected by chronic prostatitis type IIIb (CP/CPPS) by pain relieving.
All patients with clinical and instrumental diagnosis of CP/CPPS (class b) underwent DEPROX 500® 2 tablets in a single dose daily for 30 days. Clinical and microbiological analyses were carried out at the enrolment and after 1 month. NIH-CPSI and IPSS questionnaires have been used. The main outcome measure was the improvement of quality of life at the end of the whole study period, evaluated by questionnaires results.
20 men (mean age 32.8 ± 6.78) were enrolled in this pilot study. The baseline questionnaire mean scores were 25.90 ± 2.1 and 8.01 ± 3.64 for NIH-CPSI and IPSS, respectively. At the follow-up examination (1 month after treatment), 18 out of 20 patients (90.0%) reported an improvement of quality of life, in terms of pain reduction. The questionnaire results after 1 month from treatment were as follows: NIH-CPSI 12.8 ± 2.20, IPSS 7.6 ± 1.58. Statistically significant differences were then reported between the two visits, in terms of NIH-CPSI scores (p<0.001). No statistically significant differences have been reported in terms of IPSS between the two groups. All patients were negative at the Meares-Stamey test evaluation. The compliance to the study protocol was 100%.
CONCLUSIONS: The pollen extract associated with vitamins (DEPROX 500®) significantly improved total symptoms, pain, and QoL in patients with non-inflammatory CP/CPPS without severe side effects.
慢性前列腺炎/慢性盆腔疼痛综合征（CP/CPPS）的治疗效果不太令人满意，对年轻男性的生活质量影响颇大。本研究旨在评估花粉提取物联合维生素（DEPROX 500®）通过缓解疼痛来改善Ⅲb型慢性前列腺炎（CP/CPPS）年轻患者生活质量的疗效。
所有经临床和仪器诊断为CP/CPPS（b类）的患者每日单次服用2片DEPROX 500®，共30天。在入组时和1个月后进行临床和微生物学分析。使用了美国国立卫生研究院慢性前列腺炎症状指数（NIH-CPSI）和国际前列腺症状评分（IPSS）问卷。主要结局指标是在整个研究期结束时通过问卷结果评估的生活质量改善情况。
20名男性（平均年龄32.8±6.78）纳入了这项初步研究。NIH-CPSI和IPSS问卷的基线平均得分分别为25.90±2.1和8.01±3.64。在随访检查（治疗后1个月）时，20名患者中有18名（90.0%）报告生活质量因疼痛减轻而得到改善。治疗1个月后的问卷结果如下：NIH-CPSI为12.8±2.20，IPSS为7.6±1.58。然后报告两次就诊之间在NIH-CPSI评分方面存在统计学显著差异（p<0.001）。两组在IPSS方面未报告统计学显著差异。所有患者在梅尔斯-斯塔米试验评估中均为阴性。对研究方案的依从性为100%。
花粉提取物联合维生素（DEPROX 500®）可显著改善非炎性CP/CPPS患者总的症状、疼痛和生活质量，且无严重副作用。
